Table of Contents Author Guidelines Submit a Manuscript
Journal of Obesity
Volume 2010, Article ID 748048, 6 pages
http://dx.doi.org/10.1155/2010/748048
Research Article

The Role of Adipokines in Understanding the Associations between Obesity and Depression

1Mood Disorders Program, Centre for Mountain Health Services, McMaster University, D150-A, 100 West 5th Street, St. Joseph's Healthcare, Hamilton, ON, Canada L8N 3K7
2University of Calgary, 2500 University Drive Northwest Calgary, Calgary, AB, Canada T2N 1N4

Received 2 November 2009; Revised 26 May 2010; Accepted 16 June 2010

Academic Editor: Gianluca Iacobellis

Copyright © 2010 Valerie H. Taylor and Glenda M. MacQueen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. E. Wellen and G. S. Hotamisligil, “Inflammation, stress, and diabetes,” Journal of Clinical Investigation, vol. 115, no. 5, pp. 1111–1119, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. E. E. Calle and R. Kaaks, “Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms,” Nature Reviews Cancer, vol. 4, no. 8, pp. 579–591, 2004. View at Google Scholar · View at Scopus
  3. D. M. Mannino, J. Mott, J. M. Ferdinands et al., “Boys with high body masses have an increased risk of developing asthma: findings from the National Longitudinal Survey of Youth (NLSY),” International Journal of Obesity, vol. 30, no. 1, pp. 6–13, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. B. H. Brummett, J. C. Barefoot, I. C. Siegler et al., “Characteristics of socially isolated patients with coronary artery disease who are at elevated risk for mortality,” Psychosomatic Medicine, vol. 63, no. 2, pp. 267–272, 2001. View at Google Scholar · View at Scopus
  5. S. Cohen, D. A. J. Tyrrell, and A. P. Smith, “Psychological stress and susceptibility to the common cold,” The New England Journal of Medicine, vol. 325, no. 9, pp. 606–612, 1991. View at Google Scholar · View at Scopus
  6. S. Stewart-Brown, “Emotional wellbeing and its relation to health,” British Medical Journal, vol. 317, no. 7173, pp. 1608–1609, 1998. View at Google Scholar · View at Scopus
  7. B. I. Goldstein, D. E. Kemp, J. K. Soczynska, and R. S. McIntyre, “Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature,” The Journal of Clinical Psychiatry, vol. 70, no. 8, pp. 1078–1090, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Galic, J. S. Oakhill, and G. R. Steinberg, “Adipose tissue as an endocrine organ,” Molecular and Cellular Endocrinology, vol. 316, no. 2, pp. 129–136, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. X.-Y. Lu, “The leptin hypothesis of depression: a potential link between mood disorders and obesity?” Current Opinion in Pharmacology, vol. 7, no. 6, pp. 648–652, 2007. View at Publisher · View at Google Scholar · View at Scopus
  10. B. Weber-Hamann, J. Kratzsch, D. Kopf et al., “Resistin and adiponectin in major depression: the association with free cortisol and effects of antidepressant treatment,” Journal of Psychiatric Research, vol. 41, no. 3-4, pp. 344–350, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Munzberg, “Leptin-signaling pathways and leptin resistance,” Forum of Nutrition, vol. 63, pp. 123–132, 2010. View at Google Scholar · View at Scopus
  12. J. K. Elmquist, C. Bjørbæk, R. S. Ahima, J. S. Flier, and C. B. Saper, “Distributions of leptin receptor mRNA isoforms in the rat brain,” Journal of Comparative Neurology, vol. 395, no. 4, pp. 535–547, 1998. View at Publisher · View at Google Scholar · View at Scopus
  13. K. N. Frayn, F. Karpe, B. A. Fielding, I. A. Macdonald, and S. W. Coppack, “Integrative physiology of human adipose tissue,” International Journal of Obesity, vol. 27, no. 8, pp. 875–888, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. J. R. Speakman, R. J. Stubbs, and J. G. Mercer, “Does body mass play a role in the regulation of food intake?” Proceedings of the Nutrition Society, vol. 61, no. 4, pp. 473–487, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Rosická, M. Kršek, M. Matoulek et al., “Serum ghrelin levels in obese patients: the relationship to serum leptin levels and soluble leptin receptors levels,” Physiological Research, vol. 52, no. 1, pp. 61–66, 2003. View at Google Scholar · View at Scopus
  16. H. Münzberg and M. G. Myers Jr., “Molecular and anatomical determinants of central leptin resistance,” Nature Neuroscience, vol. 8, no. 5, pp. 566–570, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. K. El-Haschimi, D. D. Pierroz, S. M. Hileman, C. Bjørbæk, and J. S. Flier, “Two defects contribute to hypothalamic leptin resistance in mice with diet-induced obesity,” Journal of Clinical Investigation, vol. 105, no. 12, pp. 1827–1832, 2000. View at Google Scholar · View at Scopus
  18. X.-Y. Lu, C. S. Kim, A. Fraser, and W. Zhang, “Leptin: a potential novel antidepressant,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 5, pp. 1593–1598, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. C. S. Kim, T. Y. Huang, J. Garza et al., “Leptin induces antidepressant-like behavioral effects and activates specific signal transduction pathways in the hippocampus and amygdala of mice,” Neuropsychopharmacology, vol. 31, pp. S237–S238, 2006. View at Google Scholar
  20. I. A. Antonijevic, H. Murck, R.-M. Frieboes, R. Horn, G. Brabant, and A. Steiger, “Elevated nocturnal profiles of serum leptin in patients with depression,” Journal of Psychiatric Research, vol. 32, no. 6, pp. 403–410, 1998. View at Publisher · View at Google Scholar · View at Scopus
  21. R. T. Rubin, M. E. Rhodes, and R. K. Czambel, “Sexual diergism of baseline plasma leptin and leptin suppression by arginine vasopressin in major depressives and matched controls,” Psychiatry Research, vol. 113, no. 3, pp. 255–268, 2002. View at Publisher · View at Google Scholar · View at Scopus
  22. G.-M. Jow, T.-T. Yang, and C.-L. Chen, “Leptin and cholesterol levels are low in major depressive disorder, but high in schizophrenia,” Journal of Affective Disorders, vol. 90, no. 1, pp. 21–27, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Kraus, M. Haack, A. Schuld, D. Hinze-Selch, and T. Pollmächer, “Low leptin levels but normal body mass indices in patients with depression or schizophrenia,” Neuroendocrinology, vol. 73, no. 4, pp. 243–247, 2001. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Deuschle, W. F. Blum, P. Englaro et al., “Plasma leptin in depressed patients and healthy controls,” Hormone and Metabolic Research, vol. 28, no. 12, pp. 714–717, 1996. View at Google Scholar · View at Scopus
  25. M. A. Cimmino, G. Andraghetti, L. Briatore et al., “Changes in adiponectin and leptin concentrations during glucocorticoid treatment: a pilot study in patients with polymyalgia rheumatica,” Annals of the New York Academy of Sciences, vol. 1193, pp. 160–163, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. D. A. Sandoval and S. N. Davis, “Leptin: metabolic control and regulation,” Journal of Diabetes and Its Complications, vol. 17, no. 2, pp. 108–113, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. S. E. Wozniak, L. L. Gee, M. S. Wachtel, and E. E. Frezza, “Adipose tissue: the new endocrine organ? a review article,” Digestive Diseases and Sciences, vol. 54, no. 9, pp. 1847–1856, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. S. R. Bornstein, A. Schuppenies, M.-L. Wong, and J. Licinio, “Approaching the shared biology of obesity and depression: the stress axis as the locus of gene-environment interactions,” Molecular Psychiatry, vol. 11, no. 10, pp. 892–902, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. A. H. Berg, T. P. Combs, and P. E. Scherer, “ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism,” Trends in Endocrinology and Metabolism, vol. 13, no. 2, pp. 84–89, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Piñeiro, M. J. Iglesias, R. Gallego et al., “Adiponectin is synthesized and secreted by human and murine cardiomyocytes,” FEBS Letters, vol. 579, no. 23, pp. 5163–5169, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. A. M. Delaigle, J.-C. Jonas, I. B. Bauche, O. Cornu, and S. M. Brichard, “Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies,” Endocrinology, vol. 145, no. 12, pp. 5589–5597, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. A. M. Wolf, D. Wolf, M. A. Avila et al., “Up-regulation of the anti-inflammatory adipokine adiponectin in acute liver failure in mice,” Journal of Hepatology, vol. 44, no. 3, pp. 537–543, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. Y. Arita, S. Kihara, N. Ouchi et al., “Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity,” Biochemical and Biophysical Research Communications, vol. 257, no. 1, pp. 79–83, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. K. Narita, T. Murata, T. Takahashi, H. Kosaka, N. Omata, and Y. Wada, “Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 30, no. 6, pp. 1159–1162, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. R. Leo, G. Di Lorenzo, M. Tesauro et al., “Decreased plasma adiponectin concentration in major depression,” Neuroscience Letters, vol. 407, no. 3, pp. 211–213, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Yilmaz, “Psychopathology in the context of obesity: the adiponectin hypothesis,” Medical Hypotheses, vol. 70, no. 4, pp. 902–903, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Nagata and H. Yamada, “Psycho-neuro-immunological aspects of eating disorders,” International Congress Series, vol. 1287, pp. 279–284, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. G. Mamalakis, M. Kiriakakis, G. Tsibinos et al., “Depression and serum adiponectin and adipose omega-3 and omega-6 fatty acids in adolescents,” Pharmacology Biochemistry and Behavior, vol. 85, no. 2, pp. 474–479, 2006. View at Publisher · View at Google Scholar · View at Scopus
  39. A. Pan, X. Ye, O. H. Fanco et al., “The association of depressive symptoms with inflammatory factors and adipokines in middle-aged and older Chinese,” PLoS ONE, vol. 3, no. 1, article e1392, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. Y.-C. Chen, W.-W. Lin, Y.-J. Chen, W.-C. Mao, and Y.-J. Hung, “Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males,” Mediators of Inflammation, vol. 2010, Article ID 573594, 7 pages, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. T. You, B. J. Nicklas, J. Ding et al., “The metabolic syndrome is associated with circulating adipokines in older adults across a wide range of adiposity,” Journals of Gerontology Series A, vol. 63, no. 4, pp. 414–419, 2008. View at Google Scholar · View at Scopus
  42. S. Zeugmann, A. Quante, I. Heuser, R. Schwarzer, and I. Anghelescu, “Inflammatory biomarkers in 70 depressed inpatients with and without the metabolic syndrome,” Journal of Clinical Psychiatry. In press.
  43. J. M. Fernández-Real, A. López-Bermejo, R. Casamitjana, and W. Ricart, “Novel interactions of adiponectin with the endocrine system and inflammatory parameters,” Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 6, pp. 2714–2718, 2003. View at Google Scholar · View at Scopus
  44. W. Aldhahi and O. Hamdy, “Adipokines, inflammation, and the endothelium in diabetes,” Current Diabetes Reports, vol. 3, no. 4, pp. 293–298, 2003. View at Google Scholar · View at Scopus
  45. N. Ouchi, S. Kihara, T. Funahashi, Y. Matsuzawa, and K. Walsh, “Obesity, adiponectin and vascular inflammatory disease,” Current Opinion in Lipidology, vol. 14, no. 6, pp. 561–566, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. H. Tilg and A. M. Wolf, “Adiponectin: a key fat-derived molecule regulating inflammation,” Expert Opinion on Therapeutic Targets, vol. 9, no. 2, pp. 245–251, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Fasshauer, S. Kralisch, M. Klier et al., “Adiponectin gene expression and secretion is inhibited by interleukin-6 in 3T3-L1 adipocytes,” Biochemical and Biophysical Research Communications, vol. 301, no. 4, pp. 1045–1050, 2003. View at Publisher · View at Google Scholar · View at Scopus
  48. J. M. Bruun, A. S. Lihn, C. Verdich et al., “Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans,” American Journal of Physiology, vol. 285, no. 3, pp. E527–E533, 2003. View at Google Scholar · View at Scopus
  49. M. Fasshauer, J. Klein, S. Neumann, M. Eszlinger, and R. Paschke, “Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes,” Biochemical and Biophysical Research Communications, vol. 290, no. 3, pp. 1084–1089, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. F. Fallo, A. Scarda, N. Sonino et al., “Effect of glucocorticoids on adiponectin: a study in healthy subjects and in Cushing's syndrome,” European Journal of Endocrinology, vol. 150, no. 3, pp. 339–344, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. I. N. Holcomb, R. C. Kabakoff, B. Chan et al., “FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family,” The EMBO Journal, vol. 19, no. 15, pp. 4046–4055, 2000. View at Google Scholar · View at Scopus
  52. J. S. Flier, “The missing link with obesity?” Nature, vol. 409, no. 6818, pp. 292–293, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. O. Ukkola, “Resistin—a mediator of obesity-associated insulin resistance or an innocent bystander?” European Journal of Endocrinology, vol. 147, no. 5, pp. 571–574, 2002. View at Google Scholar · View at Scopus
  54. A. R. Shuldiner, R. Yang, and D.-W. Gong, “Resistin, obesity, and insulin resistance—the emerging role of the adipocyte as an endocrine organ,” The New England Journal of Medicine, vol. 345, no. 18, pp. 1345–1346, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. C. M. Steppan, S. T. Bailey, S. Bhat et al., “The hormone resistin links obesity to diabetes,” Nature, vol. 409, no. 6818, pp. 307–312, 2001. View at Publisher · View at Google Scholar · View at Scopus
  56. J. M. Way, C. Z. Görgün, Q. Tong et al., “Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor γ agonists,” Journal of Biological Chemistry, vol. 276, no. 28, pp. 25651–25653, 2001. View at Publisher · View at Google Scholar · View at Scopus
  57. G. Milan, M. Granzotto, A. Scarda et al., “Resistin and adiponectin expression in visceral fat of obese rats: effect of weight loss,” Obesity Research, vol. 10, no. 11, pp. 1095–1103, 2002. View at Google Scholar · View at Scopus
  58. M. W. Rajala, S. Obici, P. E. Scherer, and L. Rossetti, “Adipose-derived resistin and gut-derived resistin-like molecule-β selectively impair insulin action on glucose production,” Journal of Clinical Investigation, vol. 111, no. 2, pp. 225–230, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. C.-C. Juan, L.-C. Au, V. S. Fang et al., “Suppressed gene expression of adipocyte resistin in an insulin-resistant rat model probably by elevated free fatty acids,” Biochemical and Biophysical Research Communications, vol. 289, no. 5, pp. 1328–1333, 2001. View at Publisher · View at Google Scholar · View at Scopus
  60. C. M. Kusminski, P. G. McTernan, and S. Kumar, “Role of resistin in obesity, insulin resistance and type II diabetes,” Clinical Science, vol. 109, no. 3, pp. 243–256, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. J. Gómez-Ambrosi and G. Frübeck, “Do resistin and resistin-like molecules also link obesity to inflammatory diseases?” Annals of Internal Medicine, vol. 135, no. 4, pp. 306–307, 2001. View at Google Scholar · View at Scopus
  62. R. Rea and R. Donnelly, “Resistin: an adipocyte-derived hormone. Has it a role in diabetes and obesity,” Diabetes, Obesity and Metabolism, vol. 6, no. 3, pp. 163–170, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. J. W. Stewart, P. J. McGrath, F. M. Quitkin, and D. F. Klein, “Atypical depression: current status and relevance to melancholia,” Acta Psychiatrica Scandinavica. Supplementum, no. 433, pp. 58–71, 2007. View at Google Scholar · View at Scopus
  64. L. Brunetti, G. Orlando, L. Recinella, B. Michelotto, C. Ferrante, and M. Vacca, “Resistin, but not adiponectin, inhibits dopamine and norepinephrine release in the hypothalamus,” European Journal of Pharmacology, vol. 493, no. 1–3, pp. 41–44, 2004. View at Publisher · View at Google Scholar · View at Scopus
  65. N. M. Morton, “Obesity and corticosteroids: 11β-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease,” Molecular and Cellular Endocrinology, vol. 316, no. 2, pp. 154–164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. N. Sonino and G. A. Fava, “Psychiatric disorders associated with Cushing's syndrome: epidemiology, pathophysiology and treatment,” CNS Drugs, vol. 15, no. 5, pp. 361–373, 2001. View at Google Scholar · View at Scopus
  67. C. L. Hammen, “Stress and the course of unipolar and bipolar disorders,” in Does Stress Cause Psychiatric Illness? C. M. Mazure, Ed., vol. 56, pp. 87–110, American Psychiatric Press, Washington, DC, USA, 1995. View at Google Scholar
  68. B. S. McEwen, “Protection and damage from acute and chronic stress: allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders,” Annals of the New York Academy of Sciences, vol. 1032, pp. 1–7, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. C. F. Gillespie and C. B. Nemeroff, “Hypercortisolemia and depression,” Psychosomatic Medicine, vol. 67, no. 1, pp. S26–S28, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. J. D. Amsterdam, G. Maislin, A. Winokur, N. Berwish, M. Kling, and P. Gold, “The oCRH stimulation test before and after clinical recovery from depression,” Journal of Affective Disorders, vol. 14, no. 3, pp. 213–222, 1988. View at Publisher · View at Google Scholar · View at Scopus
  71. C. B. Nemeroff, G. Bissette, H. Akil, and M. Fink, “Neuropeptide concentrations in the cerebrospinal fluid of depressed patients treated with electroconvulsive therapy. Corticotrophin-releasing factor, β-endorphin and somatostatin,” The British Journal of Psychiatry, vol. 158, pp. 59–63, 1991. View at Google Scholar · View at Scopus
  72. P. Trayhurn and I. S. Wood, “Adipokines: inflammation and the pleiotropic role of white adipose tissue,” British Journal of Nutrition, vol. 92, no. 3, pp. 347–355, 2004. View at Publisher · View at Google Scholar · View at Scopus
  73. G. E. Miller, K. E. Freedland, R. M. Carney, C. A. Stetler, and W. A. Banks, “Pathways linking depression, adiposity, and inflammatory markers in healthy young adults,” Brain, Behavior, and Immunity, vol. 17, no. 4, pp. 276–285, 2003. View at Publisher · View at Google Scholar · View at Scopus